Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05933239
PHASE2

Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients

Sponsor: Universitair Ziekenhuis Brussel

View on ClinicalTrials.gov

Summary

Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC) planned for surgical resection.

Official title: A Phase II Study to Evaluate the Imaging Potential of 68GaNOTA-Anti-MMR VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Patients With Non-small Cell Lung Cancer (NSCLC)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2023-03-30

Completion Date

2027-04-01

Last Updated

2024-06-17

Healthy Volunteers

No

Interventions

DRUG

68GaNOTA-Anti-MMR-VHH2

Injection of the radiopharmaceutical and PET/CT imaging

Locations (1)

Universitair Ziekenhuis Brussel

Jette, Brussels Capital, Belgium